Found: 7
Select item for more details and to access through your institution.
TACkling Cancer by Targeting Selective Protein Degradation.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 10, p. 2442, doi. 10.3390/pharmaceutics15102442
- By:
- Publication type:
- Article
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-01907-9
- By:
- Publication type:
- Article
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 10, p. 5476, doi. 10.3390/ijms23105476
- By:
- Publication type:
- Article
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. 1, doi. 10.1186/s13046-019-1387-5
- By:
- Publication type:
- Article
Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2117, doi. 10.3390/cancers13092117
- By:
- Publication type:
- Article
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer.
- Published in:
- Journal of Cellular & Molecular Medicine, 2020, v. 24, n. 5, p. 3117, doi. 10.1111/jcmm.14980
- By:
- Publication type:
- Article
Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer.
- Published in:
- Nanomaterials (2079-4991), 2019, v. 9, n. 12, p. 1793, doi. 10.3390/nano9121793
- By:
- Publication type:
- Article